Skip to main content

Articles

Page 1 of 25

  1. PICALM is one of the most significant susceptibility factors for Alzheimer’s disease (AD). In humans and mice, PICALM is highly expressed in brain endothelium. PICALM endothelial levels are reduced in AD brains. ...

    Authors: Kassandra Kisler, Abhay P. Sagare, Divna Lazic, Sam Bazzi, Erica Lawson, Ching-Ju Hsu, Yaoming Wang, Anita Ramanathan, Amy R. Nelson, Zhen Zhao and Berislav V. Zlokovic
    Citation: Molecular Neurodegeneration 2023 18:7
  2. Astrocytes play a crucial, yet not fully elucidated role in the selective motor neuron pathology in amyotrophic lateral sclerosis (ALS). Among other responsibilities, astrocytes provide important neuronal home...

    Authors: Katarina Stoklund Dittlau, Lisanne Terrie, Pieter Baatsen, Axelle Kerstens, Lim De Swert, Rekin’s Janky, Nikky Corthout, Pegah Masrori, Philip Van Damme, Poul Hyttel, Morten Meyer, Lieven Thorrez, Kristine Freude and Ludo Van Den Bosch
    Citation: Molecular Neurodegeneration 2023 18:5
  3. Alzheimer’s disease (AD) is neuropathologically characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The main protein components of these hallmarks include Aβ40, Aβ42, tau, phosphor-tau, and...

    Authors: Stephanie R. Oatman, Joseph S. Reddy, Zachary Quicksall, Minerva M. Carrasquillo, Xue Wang, Chia-Chen Liu, Yu Yamazaki, Thuy T. Nguyen, Kimberly Malphrus, Michael Heckman, Kristi Biswas, Kwangsik Nho, Matthew Baker, Yuka A. Martens, Na Zhao, Jun Pyo Kim…
    Citation: Molecular Neurodegeneration 2023 18:2
  4. APOE variants are strongly associated with abnormal amyloid aggregation and additional direct effects of APOE on tau aggregation are reported in animal and human cell models. The degree to which these effects are...

    Authors: Christina B. Young, Emily Johns, Gabriel Kennedy, Michael E. Belloy, Philip S. Insel, Michael D. Greicius, Reisa A. Sperling, Keith A. Johnson, Kathleen L. Poston and Elizabeth C. Mormino
    Citation: Molecular Neurodegeneration 2023 18:1
  5. Advances in ultrasensitive detection of phosphorylated tau (p-tau) in plasma has enabled the use of blood tests to measure Alzheimer’s disease (AD) biomarker changes. Examination of postmortem brains of partic...

    Authors: Melissa E. Murray, Christina M. Moloney, Naomi Kouri, Jeremy A. Syrjanen, Billie J. Matchett, Darren M. Rothberg, Jessica F. Tranovich, Tiffany N. Hicks Sirmans, Heather J. Wiste, Baayla D. C. Boon, Aivi T. Nguyen, R. Ross Reichard, Dennis W. Dickson, Val J. Lowe, Jeffrey L. Dage, Ronald C. Petersen…
    Citation: Molecular Neurodegeneration 2022 17:85
  6. Amongst risk alleles associated with late-onset Alzheimer’s disease (AD), those that converged on the regulation of microglia activity have emerged as central to disease progression. Yet, how canonical amyloid...

    Authors: Dong Won Kim, Kevin J. Tu, Alice Wei, Ashley J. Lau, Anabel Gonzalez-Gil, Tianyu Cao, Kerstin Braunstein, Jonathan P. Ling, Juan C. Troncoso, Philip C. Wong, Seth Blackshaw, Ronald L. Schnaar and Tong Li
    Citation: Molecular Neurodegeneration 2022 17:83
  7. Microglia regulate the response to injury and disease in the brain and spinal cord. In white matter diseases microglia may cause demyelination. However, how microglia respond and regulate demyelination is not ...

    Authors: Sameera Zia, Brady P. Hammond, Martin Zirngibl, Anastasia Sizov, Charbel S. Baaklini, Sharmistha P. Panda, Madelene F. S. Ho, Kelly V. Lee, Apurba Mainali, Mena K. Burr, Sioned Williams, Andrew V. Caprariello, Christopher Power, Thomas Simmen, Bradley J. Kerr and Jason R. Plemel
    Citation: Molecular Neurodegeneration 2022 17:82
  8. Alzheimer’s disease is characterized by an abnormal increase of phosphorylated tau (pTau) species in the CSF. It has been suggested that emergence of different pTau forms may parallel disease progression. Ther...

    Authors: Johan Gobom, Andréa L. Benedet, Niklas Mattsson-Carlgren, Laia Montoliu-Gaya, Nina Schultz, Nicholas J. Ashton, Shorena Janelidze, Stijn Servaes, Mathias Sauer, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Gunnar Brinkmalm, Henrik Zetterberg, Oskar Hansson, Pedro Rosa-Neto…
    Citation: Molecular Neurodegeneration 2022 17:81
  9. Cytoplasmic mislocalization and aggregation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of the amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) disease spectrum, causing both nuclea...

    Authors: Bilal Khalil, Deepak Chhangani, Melissa C. Wren, Courtney L. Smith, Jannifer H. Lee, Xingli Li, Christian Puttinger, Chih-Wei Tsai, Gael Fortin, Dmytro Morderer, Junli Gao, Feilin Liu, Chun Kim Lim, Jingjiao Chen, Ching-Chieh Chou, Cara L. Croft…
    Citation: Molecular Neurodegeneration 2022 17:80
  10. Recent clinical and experimental studies have highlighted the involvement of Ventral Tegmental Area (VTA) dopamine (DA) neurons for the early pathogenesis of Alzheimer’s Disease (AD). We have previously descri...

    Authors: Livia La Barbera, Annalisa Nobili, Emma Cauzzi, Ilaria Paoletti, Mauro Federici, Luana Saba, Cecilia Giacomet, Ramona Marino, Paraskevi Krashia, Marcello Melone, Flavio Keller, Nicola Biagio Mercuri, Maria Teresa Viscomi, Fiorenzo Conti and Marcello D’Amelio
    Citation: Molecular Neurodegeneration 2022 17:76
  11. Abnormal lipid accumulation has been recognized as a key element of immune dysregulation in microglia whose dysfunction contributes to neurodegenerative diseases. Microglia play essential roles in the clearanc...

    Authors: Na Wang, Minghui Wang, Suren Jeevaratnam, Cassandra Rosenberg, Tadafumi C. Ikezu, Francis Shue, Sydney V. Doss, Alla Alnobani, Yuka A. Martens, Melissa Wren, Yan W. Asmann, Bin Zhang, Guojun Bu and Chia-Chen Liu
    Citation: Molecular Neurodegeneration 2022 17:75
  12. The family of VPS10p-Domain (D) receptors comprises five members named SorLA, Sortilin, SorCS1, SorCS2 and SorCS3. While their physiological roles remain incompletely resolved, they have been recognized for th...

    Authors: Alena Salasova, Giulia Monti, Olav M. Andersen and Anders Nykjaer
    Citation: Molecular Neurodegeneration 2022 17:74
  13. Alzheimer’s disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the ...

    Authors: Ana-Caroline Raulin, Sydney V. Doss, Zachary A. Trottier, Tadafumi C. Ikezu, Guojun Bu and Chia-Chen Liu
    Citation: Molecular Neurodegeneration 2022 17:72
  14. Authors: Qingyi Ma, Zhen Zhao, Abhay P. Sagare, Yingxi Wu, Min Wang, Nelly Chuqui Owens, Philip B. Verghese, Joachim Herz, David M. Holtzman and Berislav V. Zlokovic
    Citation: Molecular Neurodegeneration 2022 17:71

    The original article was published in Molecular Neurodegeneration 2018 13:57

  15. Authors: Yu-Hui Liu, Ye-Ran Wang, Qing-Hua Wang, Juan Liu and Yan-Jiang Wang
    Citation: Molecular Neurodegeneration 2022 17:64

    The original article was published in Molecular Neurodegeneration 2022 17:63

    The Research article to this article has been published in Molecular Neurodegeneration 2021 16:48

  16. Authors: Rahmouni Nesrine, Rosa-Neto Pedro and Brunet Alain
    Citation: Molecular Neurodegeneration 2022 17:63

    The Letter to the Editor to this article has been published in Molecular Neurodegeneration 2022 17:64

    The original article was published in Molecular Neurodegeneration 2021 16:48

  17. ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of the most influential risk factors for ...

    Authors: Rosalía Fernández-Calle, Sabine C. Konings, Javier Frontiñán-Rubio, Juan García-Revilla, Lluís Camprubí-Ferrer, Martina Svensson, Isak Martinson, Antonio Boza-Serrano, José Luís Venero, Henrietta M. Nielsen, Gunnar K. Gouras and Tomas Deierborg
    Citation: Molecular Neurodegeneration 2022 17:62
  18. Alzheimer’s Disease (AD) affects millions globally, but therapy development is lagging. New experimental systems that monitor neuronal functions in conditions approximating the AD brain may be beneficial for i...

    Authors: Yi-Chen Hsieh, Joseph Negri, Amy He, Richard V. Pearse II, Lei Liu, Duc M. Duong, Lori B. Chibnik, David A. Bennett, Nicholas T. Seyfried and Tracy L. Young-Pearse
    Citation: Molecular Neurodegeneration 2022 17:61
  19. Although ɑ-synuclein (ɑ-syn) spreading in age-related neurodegenerative diseases such as Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) has been extensively investigated, the role of aging in the...

    Authors: Michiyo Iba, Ross A. McDevitt, Changyoun Kim, Roshni Roy, Dimitra Sarantopoulou, Ella Tommer, Byron Siegars, Michelle Sallin, Somin Kwon, Jyoti Misra Sen, Ranjan Sen and Eliezer Masliah
    Citation: Molecular Neurodegeneration 2022 17:60
  20. Alzheimer’s disease (AD) is a neurodegenerative disorder that manifests sequential Aβ and tau brain pathology with age-dependent onset. Variants in the microglial immune receptor TREM2 are associated with enha...

    Authors: Bing Zhu, Yan Liu, Spring Hwang, Kailey Archuleta, Huijie Huang, Alex Campos, Rabi Murad, Juan Piña-Crespo, Huaxi Xu and Timothy Y. Huang
    Citation: Molecular Neurodegeneration 2022 17:58
  21. The aggregation and spread of α-synuclein (α-Syn) protein and related neuronal toxicity are the key pathological features of Parkinson’s disease (PD) and Lewy body dementia (LBD). Studies have shown that patho...

    Authors: Kai Chen, Yuka A. Martens, Axel Meneses, Daniel H. Ryu, Wenyan Lu, Ana Caroline Raulin, Fuyao Li, Jing Zhao, Yixing Chen, Yunjung Jin, Cynthia Linares, Marshall Goodwin, Yonghe Li, Chia-Chen Liu, Takahisa Kanekiyo, David M. Holtzman…
    Citation: Molecular Neurodegeneration 2022 17:57
  22. TYROBP (also known as DAP12 or KARAP) is a transmembrane adaptor protein initially described as a receptor-activating subunit component of natural killer (NK) cells. TYROBP is expressed in numerous cell types,...

    Authors: Jean-Vianney Haure-Mirande, Mickael Audrain, Michelle E. Ehrlich and Sam Gandy
    Citation: Molecular Neurodegeneration 2022 17:55
  23. Amyloid plaque deposition and axonal degeneration are early events in AD pathogenesis. Aβ disrupts microtubules in presynaptic dystrophic neurites, resulting in the accumulation of impaired endolysosomal and a...

    Authors: Leah K. Cuddy, Alia O. Alia, Miranda A. Salvo, Sidhanth Chandra, Tom N. Grammatopoulos, Craig J. Justman, Peter T. Lansbury Jr, Joseph R. Mazzulli and Robert Vassar
    Citation: Molecular Neurodegeneration 2022 17:54
  24. The Amyloid theory of Alzheimer’s disease (AD) suggests that the deposition of Amyloid β (Aβ) in the brain triggers a chain of events, involving the deposition of phosphorylated Tau and other misfolded protein...

    Authors: Tal Ganz, Nina Fainstein and Tamir Ben-Hur
    Citation: Molecular Neurodegeneration 2022 17:53
  25. Genetic mutations in beta-glucocerebrosidase (GBA) represent the major genetic risk factor for Parkinson’s disease (PD). GBA participates in both the endo-lysosomal pathway and the immune response, two important ...

    Authors: Giulietta Maria Riboldi, Ricardo A. Vialle, Elisa Navarro, Evan Udine, Katia de Paiva Lopes, Jack Humphrey, Amanda Allan, Madison Parks, Brooklyn Henderson, Kelly Astudillo, Charalambos Argyrou, Maojuan Zhuang, Tamjeed Sikder, J. Oriol Narcis, Shilpa Dilip Kumar, William Janssen…
    Citation: Molecular Neurodegeneration 2022 17:52
  26. Living organisms constantly need to adapt to their surrounding environment and have evolved sophisticated mechanisms to deal with stress. Mitochondria and lysosomes are central organelles in the response to en...

    Authors: Martin Lang, Peter P. Pramstaller and Irene Pichler
    Citation: Molecular Neurodegeneration 2022 17:50
  27. Parkinson’s disease (PD) is genetically associated with the H1 haplotype of the MAPT 17q.21.31 locus, although the causal gene and variants underlying this association have not been identified.

    Authors: Kathryn R. Bowles, Derian A. Pugh, Yiyuan Liu, Tulsi Patel, Alan E. Renton, Sara Bandres-Ciga, Ziv Gan-Or, Peter Heutink, Ari Siitonen, Sarah Bertelsen, Jonathan D. Cherry, Celeste M. Karch, Steven J. Frucht, Brian H. Kopell, Inga Peter, Y. J. Park…
    Citation: Molecular Neurodegeneration 2022 17:48
  28. Despite its identification as a key checkpoint regulator of microglial activation in Alzheimer’s disease, the overarching role of CX3CR1 signaling in modulating mechanisms of Aβ driven neurodegeneration, inclu...

    Authors: Shweta S. Puntambekar, Miguel Moutinho, Peter Bor-Chian Lin, Vaishnavi Jadhav, Danika Tumbleson-Brink, Ananya Balaji, Martin Alvarado Benito, Guixiang Xu, Adrian Oblak, Cristian A. Lasagna-Reeves, Gary E. Landreth and Bruce T. Lamb
    Citation: Molecular Neurodegeneration 2022 17:47
  29. A constant metabolism and energy supply are crucial to all organs, particularly the brain. Age-dependent neurodegenerative diseases, such as Parkinson’s disease (PD), are associated with alterations in cellula...

    Authors: Murad Al-Nusaif, Yuting Yang, Song Li, Cheng Cheng and Weidong Le
    Citation: Molecular Neurodegeneration 2022 17:46
  30. Microglia plays crucial roles in Alzheimer’s disease (AD) development. Triggering receptor expressed on myeloid cells 2 (TREM2) in association with DAP12 mediates signaling affecting microglia function. Here w...

    Authors: Peng Zhao, Yuanzhong Xu, Lu-Lin Jiang, Xuejun Fan, Zhiqiang Ku, Leike Li, Xiaoye Liu, Mi Deng, Hisashi Arase, Jay-Jiguang Zhu, Timothy Y. Huang, Yingjun Zhao, Chengcheng Zhang, Huaxi Xu, Qingchun Tong, Ningyan Zhang…
    Citation: Molecular Neurodegeneration 2022 17:44
  31. A consequence of our progressively ageing global population is the increasing prevalence of worldwide age-related cognitive decline and dementia. In the absence of effective therapeutic interventions, identify...

    Authors: Emily Connell, Gwenaelle Le Gall, Matthew G. Pontifex, Saber Sami, John F. Cryan, Gerard Clarke, Michael Müller and David Vauzour
    Citation: Molecular Neurodegeneration 2022 17:43